Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Interferon α1β for COVID-19 in Wuhan
NCT04293887Phase 1Unknown
- Sponsor
- Tongji Hospital
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Cytokines & Interferons
01
Overview
Phase 1, randomised, open-label trial of recombinant human interferon alpha-1b in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Incidence of side effects at 14 days. Status: unknown.
02
Drugs
recombinant human interferon alpha-1b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04293887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293887.